VRDN:NASDAQ, Viridian Therapeutics, Inc.
VRDN stock overview
Viridian Therapeutics, Inc. (VRDN:NASDAQ) closed at $29.96 on November 20, 2026,
down 4.71% on the day.
The stock trades 12.6% below its 52-week high of $34.29
and 127.3% above its 52-week low of $13.18.
Over the past year, it lost 1.3%.
Viridian Therapeutics, Inc. is part of the Health Care sector.
Key figures
- Price
- $29.96
- Day change
- -4.71%
- Volume
- 1,747,926
- Average volume
- 2,130,637
- Market cap
- 3B+
- 52-week range
- $13.18 – $34.29
- 50-day average
- $23.35
- 200-day average
- $21.52
Price action over the past year
In 252 trading sessions since November 20, 2025, VRDN closed higher on 123 days (49%).
Its best day was May 5, 2026 (+33.36%) and its worst was March 30, 2026 (-32.35%).
The stock moved 10% or more in a single session 5 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
VRDN news
-
Nov 20, 2026:
Viridian Therapeutics (VRDN) Shares Jumped, What Is Behind The Latest Attention?
-
Nov 19, 2026:
Viridian Therapeutics initiated at 'buy' by Bank of America with $47 price target
-
Nov 19, 2026:
Viridian Therapeutics' Lumvoa Emerging as Rival to Amgen's Tepezza, BofA Securities Says
-
Nov 17, 2026:
Thyroscope and TORC Announce Strategic Collaboration to Advance AI-Driven Precision Medicine in Thyroid Eye Disease
-
Nov 9, 2026:
Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says
-
Nov 9, 2026:
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
-
Nov 8, 2026:
Viridian Therapeutics Inc (VRDN) (Q3 2026) Earnings Call Highlights: Lumvoa's Strong Debut With ...
-
Nov 6, 2026:
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
About Viridian Therapeutics, Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Similar stocks
Find more stocks like VRDN with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.